T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.,Trends in Immunology

当前位置： X-MOL 学术 › Trends Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Trends in Immunology ( IF 13.1 ) Pub Date : 2019-03-01 , DOI: 10.1016/j.it.2019.01.008
Belén Blanco ₁ , Marta Compte ₂ , Simon Lykkemark ₃ , Laura Sanz ₂ , Luis Alvarez-Vallina ₄

Affiliation

The redirection of T cell activity towards cancer cells via targeting of tumor-associated antigens (TAAs) by soluble bispecific antibodies (bsAbs) or membrane-anchored chimeric antigen receptors is one of the most promising cancer immunotherapy strategies currently in development. We review here an emerging approach that combines aspects of antibody- and cell-based therapies: STAb immunotherapy, based on the endogenous secretion of T cell-redirecting bsAbs (STAb). STAb immunotherapies use ex vivo or in vivo genetic modifications of different cell types with nucleic acids or viral vectors encoding bsAbs; these can result in effective and persistent concentrations of antibodies. After introducing core concepts, we discuss plausible ways by which STAb strategies might be further developed to improve their potential efficacy and safety in preclinical and clinical testing.

中文翻译：

针对“ STAb”肿瘤的T细胞重定向策略：除了CAR和双特异性抗体之外。

通过可溶性双特异性抗体（bsAbs）或膜锚定的嵌合抗原受体靶向肿瘤相关抗原（TAA），将T细胞活性重定向至癌细胞是目前正在开发的最有前途的癌症免疫治疗策略之一。我们在这里回顾一种结合抗体和细胞疗法的新方法：STAb免疫疗法，基于T细胞重定向bsAbs（STAb）的内源性分泌。STAb免疫疗法通过编码bsAbs的核酸或病毒载体对不同细胞类型进行离体或体内遗传修饰；这些可以导致抗体的有效和持久浓度。在介绍了核心概念之后，

更新日期：2019-02-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南